Daily startup and blockchain data-wiki with interviews, Q&A's & discussions about funding rounds & investors.

RaisedToday moderators manually update and approve wiki edits - check back every 1-2h for approved submissions.

Contributed by laura998

Algeta

3 Disclosed Funding Rounds $108,850,001

0 Participating Investments


Chemical, Biotechnology, Medical

Algeta ASA, an oncology company, focused on developing targeted therapies for patients with cancer based on its alpha-pharmaceutical

Oslo, Oslo, Norway, Europe (NO)

Organizations in Oslo in Chemical,
Organizations in Oslo in Biotechnology,
Organizations in Oslo in Medical,
Organizations in Oslo in Chemical,
Organizations in Oslo in Biotechnology,
Organizations in Oslo in Medical,
Organizations in Norway in Chemical,
Organizations in Norway in Biotechnology,
Organizations in Norway in Medical,
Organizations in Europe in Chemical,
Organizations in Europe in Biotechnology,
Organizations in Europe in Medical

Investors in Oslo in Chemical,
Investors in Oslo in Biotechnology,
Investors in Oslo in Medical,
Investors in Oslo in Chemical,
Investors in Oslo in Biotechnology,
Investors in Oslo in Medical,
Investors in Norway in Chemical,
Investors in Norway in Biotechnology,
Investors in Norway in Medical,
Investors in Europe in Chemical,
Investors in Europe in Biotechnology,
Investors in Europe in Medical

Scandinavia (0 Investors) (0 Startups), Nordic Countries (0 Investors) (0 Startups)

Founded date 01, 1997

Operating Status Active

Funding Stage M&A

Last Funding Type Post-IPO Equity

Company Type For Profit

Website algeta.com

Contact Hunter Lookup


Twitter Link

Wikipedia Link

Algeta ASA, an oncology company, focused on developing targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. Its lead product includes radium-223 dichloride, which completed Phase III clinical trial to treat castration-resistant prostate cancer with bone metastases. The company is also developing alpha-emitter thorium-227 that is in the preclinical phase linked to tumor-targeting molecules to form targeted thorium conjugates. It has an agreement with Bayer Pharma AG for the development and commercialization of radium-223 worldwide. The company was formerly known as Anticancer Therapeutic Inventions AS and changed its name to Algeta ASA in 2003. Algeta ASA was founded in 1997 and is headquartered in Oslo, Norway.

Date Round Raised Lead
February, 22, 2012 Post-IPO Equity $45,000,000 -------
February, 18, 2009 Post-IPO Equity $35,000,000 Abingworth
September, 02, 2005 Series A $28,850,001 -------

Algeta Investors (6)

Investor Lead? Round Participating Raise Date Partners
Abingworth Yes Post-IPO Equity $35,000,000 February, 18, 2009 -------
SR One No Series A $28,850,001 September, 02, 2005 -------
Advent Venture Partners No Series A $28,850,001 September, 02, 2005 -------
NorgesInvestor No Series A $28,850,001 September, 02, 2005 -------
HealthCap No Series A $28,850,001 September, 02, 2005 -------
Advent Life Sciences No Series A $28,850,001 September, 02, 2005 -------